Fukumoto T.; Zhu H.; Nacarelli T.; Karakashev S.; Fatkhutdinov N.; Wu S.; Liu P.; Kossenkov A.; Showe L.; Jean S.; Zhang L.; Zhang R.
(2019)
© 2019 American Association for Cancer Research. Despite the high initial response rates to PARP inhibitors (PARPi) in BRCA-mutated epithelial ovarian cancers (EOC), PARPi resistance remains a major challenge. Chemical ...